Total Payments
$253,665
2024 Payments
$61,361
Companies
28
Transactions
301
Medicare Patients
598
Medicare Billing
$125,495
Payment Breakdown by Category
Consulting$205,166 (80.9%)
Travel$30,083 (11.9%)
Food & Beverage$8,752 (3.5%)
Other$8,596 (3.4%)
Research$951.23 (0.4%)
Education$116.59 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $205,166 | 78 | 80.9% |
| Travel and Lodging | $30,083 | 74 | 11.9% |
| Food and Beverage | $8,752 | 139 | 3.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,096 | 1 | 2.0% |
| Honoraria | $3,500 | 2 | 1.4% |
| Unspecified | $951.23 | 3 | 0.4% |
| Education | $116.59 | 4 | 0.0% |
Payments by Type
General
$252,714
298 transactions
Research
$951.23
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $54,194 | 54 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $39,188 | 63 | $0 (2024) |
| AstraZeneca UK Limited | $24,980 | 24 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $22,517 | 48 | $0 (2024) |
| Novocure Inc. | $20,677 | 28 | $0 (2024) |
| GENZYME CORPORATION | $16,949 | 13 | $0 (2022) |
| Merck Sharp & Dohme LLC | $12,067 | 17 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $7,600 | 1 | $0 (2023) |
| EMD Serono, Inc. | $7,339 | 8 | $0 (2018) |
| BioNTech SE | $6,201 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,361 | 68 | Novocure Inc. ($18,845) |
| 2023 | $69,083 | 104 | Regeneron Pharmaceuticals, Inc. ($22,847) |
| 2022 | $63,489 | 37 | E.R. Squibb & Sons, L.L.C. ($22,129) |
| 2021 | $28,296 | 13 | E.R. Squibb & Sons, L.L.C. ($5,850) |
| 2020 | $4,333 | 3 | Daiichi Sankyo Inc. ($3,083) |
| 2019 | $1,507 | 12 | AstraZeneca Pharmaceuticals LP ($1,385) |
| 2018 | $15,183 | 19 | AstraZeneca UK Limited ($7,947) |
| 2017 | $10,413 | 45 | E.R. Squibb & Sons, L.L.C. ($8,105) |
All Payment Transactions
301 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/23/2024 | BioNTech SE | — | Consulting Fee | Cash or cash equivalent | $6,162.50 | General |
| 09/27/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
| 08/20/2024 | ADC Therapeutics America, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 08/08/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Consulting Fee | Cash or cash equivalent | $4,900.00 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Travel and Lodging | Cash or cash equivalent | $322.55 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $130.29 | General |
| Category: Oncology | ||||||
| 08/07/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 08/07/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $5,719.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Consulting Fee | Cash or cash equivalent | $1,634.00 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $92.50 | General |
| Category: ONCOLOGY | ||||||
| 07/26/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $52.00 | General |
| Category: ONCOLOGY | ||||||
| 06/28/2024 | Daiichi Sankyo Inc. | — | Education | In-kind items and services | $52.50 | General |
| 06/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Education | In-kind items and services | $52.50 | General |
| Category: ONCOLOGY | ||||||
| 06/24/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $74.42 | General |
| Category: Oncology | ||||||
| 06/24/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $73.07 | General |
| Category: Oncology | ||||||
| 06/23/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Travel and Lodging | Cash or cash equivalent | $391.00 | General |
| Category: Oncology | ||||||
| 06/20/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Consulting Fee | Cash or cash equivalent | $1,400.00 | General |
| Category: Oncology | ||||||
| 06/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Travel and Lodging | In-kind items and services | $517.44 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $121.04 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $103.57 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $79.98 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $38.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2 STUDY OF REGN5093-M114 (METXMET ANTIBODY-DRUG CONJUGATE) IN PATIENTS WITH MET OVEREXPRESSING ADVANCED CANCER | Regeneron Pharmaceuticals, Inc. | $951.23 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 148 | 291 | $108,385 | $33,694 |
| 2022 | 2 | 120 | 242 | $82,060 | $29,721 |
| 2021 | 3 | 150 | 261 | $86,213 | $31,927 |
| 2020 | 3 | 180 | 320 | $102,011 | $30,153 |
Total Patients
598
Total Services
1,114
Medicare Billing
$125,495
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 81 | 179 | $69,906 | $20,964 | 30.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 58 | $15,647 | $5,859 | 37.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 24 | 24 | $13,023 | $3,696 | 28.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 14 | $5,497 | $1,614 | 29.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 16 | 16 | $4,311 | $1,561 | 36.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 72 | 186 | $59,864 | $22,307 | 37.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 30 | 30 | $13,828 | $4,643 | 33.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 26 | $8,368 | $2,771 | 33.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 65 | 142 | $45,703 | $17,719 | 38.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 42 | 42 | $19,359 | $6,777 | 35.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 16 | 47 | $11,496 | $4,181 | 36.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 27 | 30 | $9,656 | $3,250 | 33.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 81 | 173 | $55,680 | $16,490 | 29.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 47 | 74 | $23,817 | $7,099 | 29.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 23 | 23 | $10,601 | $3,359 | 31.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 17 | 37 | $8,815 | $2,403 | 27.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 12 | 13 | $3,097 | $802.01 | 25.9% |
About Dr. Patrick Forde, M.D
Dr. Patrick Forde, M.D is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/07/2011. The National Provider Identifier (NPI) number assigned to this provider is 1467733113.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Forde, M.D has received a total of $253,665 in payments from pharmaceutical and medical device companies, with $61,361 received in 2024. These payments were reported across 301 transactions from 28 companies. The most common payment nature is "Consulting Fee" ($205,166).
As a Medicare-enrolled provider, Forde has provided services to 598 Medicare beneficiaries, totaling 1,114 services with total Medicare billing of $125,495. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Baltimore, MD
- Active Since 09/07/2011
- Last Updated 01/05/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1467733113
Products in Payments
- LIBTAYO (Biological) $35,665
- Optune Lua (NovoTTF-200T) (Device) $18,845
- IMFINZI (Biological) $15,183
- OPDIVO (Biological) $14,342
- RYBREVANT (Drug) $3,710
- TECENTRIQ (Biological) $3,515
- LUMAKRAS (Drug) $3,245
- Enhertu (Drug) $3,135
- ILARIS (Biological) $2,025
- TAGRISSO (Drug) $1,507
- COSELA (Drug) $1,500
- KEYTRUDA (Biological) $1,114
- BRUKINSA (Drug) $891.25
- IMFINZI (Drug) $101.08
- ALIMTA (Drug) $34.85
- FOUNDATIONONE (Device) $25.00
- Non-Covered Product (Drug) $11.23
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Hematology & Oncology $814,882
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816
Dr. Maria Baer, Md, MD
Hematology & Oncology — Payments: $99,851
Hematology & Oncology $99,851